Welcome to our dedicated page for Petvivo Hldgs news (Ticker: PETV), a resource for investors and traders seeking the latest updates and insights on Petvivo Hldgs stock.
PetVivo Holdings develops and commercializes veterinary medical devices and biomedical therapeutics for companion animals and equines through PetVivo Animal Health and PetVivo AI. Its recurring company updates center on Spryng with OsteoCushion Technology, a veterinarian-administered intra-articular injection for joint-related conditions including lameness and osteoarthritis, and PrecisePRP, an off-the-shelf platelet-rich plasma product for veterinary use.
News also covers regulatory acknowledgements, product availability, licensing and commercialization activity, PetVivo.ai and AgenticPet AI technology, fiscal results, conference presentations, and capital-market communications. The company describes a strategy of applying human therapies to animal health and protects its biomaterials, products, production processes and methods of use through patents and trade secrets.
PetVivo Holdings, Inc. (NASDAQ: PETV) announced Mark Middleton as the new National Director of Sales. His 38 years of experience in the Animal Health Industry, including leadership roles at Animal Health International, is expected to enhance sales of PetVivo's spryng™ product, which utilizes OsteoCushion Technology for treating osteoarthritis in pets. The company aims to accelerate revenue generation by leveraging innovative medical therapeutics for companion animals. The lead product is set for expanded commercial sale later this year.
PetVivo Holdings, Inc. (NASDAQ: PETV) will exhibit at the Western Veterinary Conference in Las Vegas from September 6-9, 2021. The company aims to showcase its lead product, SPRYNG™ with OsteoCushion™ Technology, designed for treating joint afflictions in pets. The conference is the largest veterinary event in the Western U.S., attracting over 15,000 participants. PetVivo CEO John Lai expressed optimism about forming industry connections to advance SPRYNG's development and commercialization, with broader sales expected in Q4.
PetVivo Holdings (NASDAQ: PETV) appoints Dr. Ann Zieser as Senior Technical Veterinarian, enhancing the company's veterinary expertise. Dr. Zieser brings over 31 years of experience in veterinary medicine, specializing in companion animal care. She aims to support the introduction of SPRYNG™, a treatment for osteoarthritis in pets, which is set for expanded commercial sales later this year. PetVivo focuses on innovative treatments for companion animals, leveraging human therapies for faster market entry.
PetVivo Holdings, Inc. (NASDAQ: PETV) has rebranded its therapeutic osteoarthritis product as “SPRYNG”. This change reflects the product's focus on enhancing mobility and quality of life for pets. SPRYNG utilizes OsteoCushion Technology, which supports joint health by replacing damaged cartilage and aiding tissue healing. The product is set for expanded commercial sales later this year and is backed by a robust pipeline of seventeen animal therapeutic products and twenty-one protective patents. CEO John Lai and Marketing Director Russ Siakel emphasize the life-changing benefits of SPRYNG for companion animals.
PetVivo Holdings, Inc. (NASDAQ: PETV) announced the appointment of Russell Siakel as the new Director of Marketing. Siakel, who has consulted for the Company since January 2021, brings over 30 years of experience in the animal health industry, previously working with Pfizer Animal Health and Boehringer Ingelheim. He aims to enhance the company's marketing efforts and product awareness. PetVivo focuses on innovative medical therapeutics for companion animals, with a portfolio of 17 products and 21 patents, including their lead product Kush, targeting osteoarthritis treatment in dogs and horses.
PetVivo Holdings, Inc. (NASDAQ: PETV) announces its participation in the Emerging Growth Conference on August 18, 2021, at 10:15 AM ET. This event will feature an interactive presentation by CEO John Lai, allowing investors to engage and ask questions in real time. PetVivo focuses on innovative medical therapeutics for pets, with a product pipeline including its lead offering, Kush, aimed at treating osteoarthritis in dogs and horses. An archived webcast will be available for those unable to attend live.
PetVivo Holdings closed its public offering of 2,500,000 units at $4.50 each, raising approximately $11.25 million. Each unit comprises one common stock share and a warrant to purchase one share at $5.625, exercisable immediately for five years. The offering, which included an over-allotment option of 375,000 warrants exercised by the underwriter, supports marketing, R&D, and debt repayment. The stock began trading on Nasdaq under the symbols PETV and PETVW on August 11, 2021.
PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) has announced a public offering of 2,500,000 units at $4.50 each, raising approximately $11.25 million. Each unit consists of one share of common stock and one warrant, which can be exercised at $5.625 over five years. The offering is expected to close on August 13, 2021, with proceeds used for marketing, debt repayment, R&D, and working capital. ThinkEquity is the sole book-running manager. The common stock and warrants are set to begin trading on August 11, 2021.
PetVivo Holdings, Inc. (OTCQB:PETV) announced the issuance of a new patent from the USPTO for its proprietary encapsulated or coated stent systems. This patent covers a broad range of products, including biocompatible stents aimed at therapies for both humans and companion animals. With this patent, the company's intellectual property portfolio now includes 21 allowed patents, nine of which are U.S. patents. Additionally, PetVivo has 17 more applications pending, advancing its mission to innovate in the biomedical device sector for pets.
PetVivo Holdings, Inc. (OTCQB: PETV) has announced the appointment of Robert J. Folkes as its new Chief Financial Officer. Folkes, with extensive experience in medical device firms, previously held key roles at Tactile Systems Technology and Advanced Respiratory. CEO John Lai expressed excitement about Folkes' expertise contributing to the company's mission to develop innovative therapeutics for pets. PetVivo is focused on commercializing unique medical devices, including its lead product, Kush, aimed at treating osteoarthritis in animals.